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Abstract: The infection by mucosal human papillomavirus (HPV) is causally associated with tumor development in cer-
vix and oropharynx. The mechanisms responsible for this oncogenic potential are mainly due to the product activities of 
two early viral oncogenes: E6 and E7. Although a large number of cellular targets have been described for both oncopro-
teins, the interaction with tumor suppressors p53 and retinoblastoma protein (pRb) emerged as the key functional activi-
ties. E6 degrades tumor suppressor p53, thus inhibiting p53-dependent functions, whereas E7 binds and degrades pRb, al-
lowing the transcription of E2F-dependent genes. Since these two tumor suppressors exert their actions through transcrip-
tional modulation, functional genomics has provided a large body of data that reflects the altered gene expression of HPV-
infected cells or tissues. Here we will review the similarities and differences of these findings, and we also compare them 
with those obtained with transgenic mouse models bearing the deletion of some of the viral oncogene targets. The com-
parative analysis supports molecular evidences about the role of oncogenes E6 and E7 in the interference with the men-
tioned cellular functions, and also suggests that the mentioned transgenic mice can be used as models for HPV-associated 
diseases such as human cervical, oropharynx, and skin carcinomas. 
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INTRODUCTION 
 Human papillomaviruses (HPV) are the etiological agents 
responsible for a number of pathologies affecting the strati-
fied epithelia of the skin and anogenital and oropharyngeal 
sites [1-3]. Specific HPV types (“low risk” HPVs) cause 
benign warts, but other types (“high risk” HPVs) are strongly 
associated with premalignant and malignant invasive carci-
nomas, especially in the uterine cervix. Cervical cancer (CC) 
is the second most frequent type of women cancer world-
wide, being especially important in the developing countries, 
where gynecological screening is not sufficiently imple-
mented in the clinical routine [3]. Although less frequently, 
HPV infections have also been associated with carcinoma 
development in skin and oropharynx. Overall, about 25% of 
the head and neck squamous cell carcinomas (HNSCCs) are 
infected with “high risk” HPVs, and display clinical and mo-
lecular features that distinguish them from the remaining 
HNSCCs [4]. 
  Multiple molecular studies have reported that HPV-
mediated carcinogenesis is mainly due to the oncogenic ac-
tivities of the viral early proteins E6 and E7. E6 is able to 
induce the degradation of p53 via direct binding to the ubiq-
uitin ligase E6AP, inhibiting p53-dependent signaling upon 
stress stimuli, and contributing to tumorigenesis [5-7]. On 
the other hand, E7 oncoprotein E7 associates with the retino-
blastoma family of proteins (pRb, p107 and p130) and dis-
rupts their association with the E2F family of transcription 
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factors, subsequently transactivating cellular proteins re-
quired for cellular and viral DNA replication. Moreover, E7 
binds and induces the proteasomal-mediated degradation of 
all pRb, p107 and p130 proteins [8-10]. p53 and pRb are 
well-known cellular tumor suppressors involved in processes 
such as cell cycle progression, DNA repair, apoptosis, dif-
ferentiation, senescence, and chromatin remodeling. Very 
importantly, in the vast majority of human tumors pRb 
and/or p53 functions are impaired. 
  Recently, preventive vaccination against HPV infections 
has been launched in some countries, protecting from most 
of the benign and malignant lesions in the cervix. Epidemi-
ological studies estimate that about 10% of the women popu-
lation is already infected with “high risk” mucosal HPVs in 
the genital area, population in which vaccination would not 
be worthy, as it is not curative. Although the infection is not 
sufficient (but necessary) for tumor development, it is impor-
tant to develop curative therapies for HPV-related carcino-
genesis [11]. 
  Gene expression profiling analysis using DNA microar-
ray technologies has emerged in the last decade as a power-
ful tool to search for reliable gene markers of specific can-
cers, to determine the molecular features than distinguished 
or grouped different histological types of cancers, and to 
correlate specific gene expression patterns with clinical out-
come [12]. Moreover, microarray analysis provides a power-
ful tool to compare molecular features of mouse models of 
human cancer and their human counterparts [12]. A large 
number of reports have described gene expression deregula-
tion of cervical cancer and HPV-infected or non-infected 
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genes observed in the infected tumors have been described in 
previous studies of in vitro HPV-models, either from basic 
analysis of viral oncogenic mechanisms or from gene ex-
pression profiling analysis [24-31]. 
  In this review, we compare data of deregulated genes 
from HPV-infected human cervical and oropharyngeal tu-
mors,  in vitro cell models of oncogenic HPV, and animal 
mouse models bearing the deletion of retinoblastoma family 
and/or p53 genes. The comparison helps to define molecular 
similarities between cervical and oropharyngeal HPV-
infected tumors, and also between the human tumors and 
different models of the HPV-associated disease. The report 
also emphasizes the need to perform simultaneous analysis 
of multitude of HPV-infected and non-infected cervical and 
oropharyngeal carcinomas, with full clinical information in 
order to extract accurate molecular signatures associated 
with HPV-infection, and/or with clinical outcome. 
PATTERNS OF OVEREXPRESSED GENES IN HPV-
INFECTED TUMORS 
  Gene expression profiles of HPV-infected human tumors 
with normal, uninfected tissue have been described. Most of 
these studies have been done on CC, although some have 
been performed in HNSCC. These analyses have allowed 
authors to find genes related to HPV-related tumor progres-
sion or expression patterns of HPV-related tumors. As ex-
pected, some of the genes described in these comparisons are 
well known markers of infection as previously described in 
basic molecular studies of papillomavirus oncogene activi-
ties, or in screening of markers using human clinical sam-
ples. Generally, gene expression deregulation caused by pa-
pillomavirus infection is related to cell cycle genes, most of 
them E2F genes and E2F-regulated genes. These findings are 
in agreement with oncogenic activities of the E7 viral early 
gene, able to bind and inactivate members of the retinoblas-
toma proteins pRb, p107 and p130, which act as repressors 
of E2F transcription factors. However, expression profiling 
has helped to delimitate other previously unknown genetic 
factors related to HPV-induced carcinogenesis, some of 
which could represent markers of virus-mediated malignancy 
and/or targets for therapeutic intervention. 
  In order to find common hallmarks of HPV related car-
cinogenesis, we decided to compare published gene lists of 
microarray analyses. Firstly, we focused on the studies per-
formed in cervical cancer, whereby normal cervical tissue or 
low-grade squamous intraepithelial lesion (LSIL) were com-
pared with high grade squamous intraepithelial lesions 
(HSIL) or with CC. Up to seven reports were used for com-
parison (Table 1), performed in three different microarray 
platforms. We selected those genes that were overexpressed 
Table 1.  Gene Expression Microarray Analysis of Human HPV-Related Cancer 
Tissue Comparative 
Number 
Samples 
Gene Cluster 
Cluster  
Size 
Reference 
Cervix  Normal cervix and LSIL versus HSIL, SCC and ACA  17 versus 17  UP in HSIL, SCC and ACA  46  [13] 
Cervix Normal  cervix  versus cancer cell lines and CC  16 versus 31  UP in cancer  80  [15] 
Cervix Normal  mucosa  versus cancer cell lines, ACA, and SCC  5 versus 35  UP in cancer  993  [17] 
UP in cancer  22 
Cervix Normal  cervix  versus CC  8 versus 26 
DOWN in cancer  5 
[22] 
UP in cancer  21 
Cervix Normal  cervix  versus CC  18 versus 29 
DOWN in cancer  81 
[21] 
UP in cancer  29 
Cervix  Normal cervix and HSIL versus CC  17 versus 21 
DOWN in cancer  31 
[23] 
Cervix Normal  cervix  versus cancer cell lines and CC  20 versus 29  UP in cancer  29  [19] 
UP in cancer  220 
Head and neck  Normal oral tissue versus oropharyngeal cancer HPV+  4 versus 3 
DOWN in cancer  175 
[14] 
UP in HPV+  128 
Head and neck  Oropharyngeal HPV+ versus oropharyngeal cancer HPV-  3 versus 4 
DOWN in HPV+  40 
[14] 
UP in HPV+  58 
Head and neck  HNSCC HPV+ versus HNSCC HPV-  12 versus 30 
DOWN in HPV+  61 
[18] 
Head and neck  HNSCC HPV+ versus HNSCC HPV-  8 versus 28  UP in HPV+  86  [20] 
UP in HPV+  108  Cervix and  
Head and neck 
CC and HNSCC HPV+ versus CC and HNSCC HPV-  43 versus 18 
DOWN in HPV+  10 
[16] 28    Current Genomics, 2009, Vol. 10, No. 1  Buitrago-Pérez et al. 
 
in at least 3 out of 7 reports, giving rise to 14 common genes 
of HPV-related cervical cancer (Signature 1, see Table 2). If 
we extend the analysis including a report whereby normal 
oral tissue was compared to HPV-infected oropharyngeal 
carcinomas, new common genes appear in at least 3 of the 
studies, resulting in a group of 28 genes (Signature 2). This 
signature represents genes differentially expressed between 
normal, non-malignant samples and HPV-infected carcino-
mas from mucosal tissues. 
  In a second analysis, we performed a comparison be-
tween HPV-infected versus non infected HNSCC from 3 
different studies using two distinct platforms. Only 7 genes 
displayed similar results in at least 2 studies (Signature 3, 
Table  2), representing genes that could distinguish HPV-
related induced carcinogenesis from non viral mechanisms 
of HNSCC tumorigenesis. If we include in the comparison 
an analysis of the genes deregulated in HPV-infected carci-
nomas of both CC and HNSCC, the number of common 
genes in at least 2 studies increased to 35 (Signature 4, Table 
2). Of note, none of the genes obtained in this comparison is 
present in the Signature 1, suggesting that major differences 
between HPV-positive and negative cancers are distinguish-
able from the differences between normal and tumoral tissue. 
However, shared molecular determinants of both compari-
sons can be limited, since we compare the reported expres-
sion lists of deregulated genes. However, less than half of the 
described reports have allocated raw data of the complete 
gene expression data in public repositories, thus precluding 
the collection of complete records of the published studies 
and the differential expression analysis in a multiexperiment 
dataset. 
  In a third analysis, we decided to perform a global com-
parison of molecular similarities between normal versus 
HPV-tumoral samples and HPV-infected versus uninfected 
samples of all mentioned reports. Signature 5 (Table 2) con-
tains 26 genes overexpressed in 3 or more comparisons out 
of 12, representing a HPV-infected mucosal carcinoma sig-
nature. Detailed functional analysis of the HPV-tumor in-
fected signature (Signature 5) using enrichment of Gene On-
tology biological processes associated with the 26 genes evi-
denced that virus induces a clear deregulation in cell cycle 
genes, as it has been already described. Fig. (1) shows the 
result of the functional analysis performed using DAVID 
Functional Annotation web tool [32, 33], where the most 
relevant enriched terms are included. Genes involved in 
DNA replication, DNA repair, cell cycle control or mitosis 
are present. Interestingly, they also appear 3 genes involved 
in proteolysis within the term “ubiquitin-dependent protein 
catabolic process”: USP1, UBE2C and PSMB9. 
PATTERNS OF UNDEREXPRESSED GENES IN HPV-
INFECTED TUMORS 
  From the studies that have been used to check for com-
mon overexpressed genes, there are only 7 comparisons con-
taining repressed genes, being 4 comparisons of normal ver-
sus carcinoma samples (3 CC and 1 HNSCC) and 3 compari-
sons of HPV-positive versus negative samples. Only an 
analysis of common genes between all of them was possible, 
resulting in a number of 31 genes downregulated in 2 or 
more comparisons out of 7 (Signature 6). This signature rep-
resents genes that are underexpressed in HPV-infected mu-
cosal carcinomas. The functional analysis based on the GO 
database (Fig. (1)) showed that the number of enriched func-
tions and their statistical significance is lower than the ob-
served for up-regulated genes. Proteases belonging to the 
family of kallikreins (KLK7, KLK8, KLK10, KLK11 and 
KLK13) are highly represented in a term named “proteoly-
sis”. Other interesting functions are some related to “epider-
mis development” or “keratinocyte differentiation”. 
HPV-INFECTED MUCOSAL CARCINOMA SIGNA-
TURE DURING CERVICAL CARCINOMA PRO-
GRESSION 
  Gius and collaborators [26] have reported an analysis of 
the changes in genomic expression that occur as normal cer-
vical tissue progresses to carcinoma in situ (CIN) an then to 
cervical carcinoma, in either epithelium or stromal compart-
ments using laser capture microdissection. Up to 5 genes 
belonging to the Signature 5 were reported to be overex-
pressed during cancer progression, but exclusively within the 
epidermal compartment: CDKN2A, CENPF, MCM2, RFC4 
and TK1. On the other hand, downregulated genes in epi-
dermal cells during malignant progression that are present in 
the HPV-tumor associated Signature 6 were: KLK11, CDA, 
CRABP2, CDA and KIF1C. These results corroborates the 
HPV-tumor associated deregulation of some of the genes of 
the Signatures 5 and 6 (Table 3), and demonstrate that these 
genes are particularly deregulated into the epidermal (but no 
stromal) component of the carcinomas. 
IN VITRO SYSTEMS FOR HPV-INDUCED GENE EX-
PRESSION DEREGULATION 
  A few reports have described the effect of viral oncogene 
expression in cellular or organotypic cultures. Duffy and 
collaborators used human foreskin primary keratinocytes 
retrovirally transduced with both HPV16 E6 and E7 onco-
genes, or E7 in the presence of 2 different E6 mutants [24]. 
Comparison of genes described as differentially expressed in 
the transduced cells showed no overlap with Signature 5 of 
HPV-induced carcinomas. On the other hand, comparison of 
underexpressed genes showed an overlap of 4 genes with 
Signature 6 (KLK7, SULT2B1, ECM1 and LY6D) (Table 
3). Furthermore, Wan and collaborators performed a similar 
analysis, but using immortalized human primary keratino-
cytes transfected with the head-to-tail dimer of HPV16 DNA 
[31]. Comparisons of genes deregulated with normal primary 
cells gave rise to an overlap of only 1 overexpressed gene 
with Signature 5 (CDKN2A) and 6 underexpressed genes 
with Signature 6 (KLK10, KLK11, SCEL, KLK7, LY6D and 
S100P) (Table 3). Results suggest that the cellular systems 
used could not mimic gene overexpression of HPV-associa- 
ted carcinomas, although they could induce some of the ex-
pression patterns of downregulated genes. 
  Furthermore, Garner-Hamrick and collaborators reported 
a microarray analysis of organotypic cultures of human pri-
mary keratinocytes retrovirally transduced with the E6 and 
E7 oncogenes of HPV18 under the control of the native dif-
ferentiation-dependent HPV enhancer-promoter [25]. Results 
showed overlaps of over- and under-expressed genes with 
the comparative Signatures 5 and 6, respectively (Table 3), Molecular Signature of HPV-Induced Carcinogenesis  Current Genomics, 2009, Vol. 10, No. 1    29 
 
Table 2.  Overlap between HPV-Tumor Microarray Analysis 
Signature 1  Signature 2  Signature 3  Signature 4  Signature 5  Signature 6 
Genes Studies Genes Studies Genes Studies Genes Studies Genes Studies Genes Studies 
APOC1 3 APOC1 3  C7ORF46  2  ANKRD32  2  CDC7  4 KLK10 5 
CDKN2A 3 ATP13A3 3 CDKN2C 2  C16ORF75  2 CDKN2A 6  KLK8  4 
E2F1 3 BST2 3  CXCR7  2  C5ORF34  2  CDKN2C  4  CRABP2  3 
ECT2  3 CDKN2A 4  ITPKB  2 C7ORF46 2  CENPF  3  KLK11  2 
MCM2 3 DDIT4 3 MDM1 2 CDC7 2 DHFR 3 KLK13 2 
MMP9  3 E2F1 3  SYCP2  3  CDKN2A  2 DTL 4 PRSS3  2 
MYBL2  3 ECT2 3  SYNGR3  2  CDKN2C  3 E2F1 3 SCEL 2 
PCNA 3 IFI27 3      CENPK  2 ECT2 3  CDA 2 
PLOD2  3  MCM2  4     CXCR7  2 EZH2 3 CPA4 2 
RFC4 3 MELK 3      DHFR 2 KIF15 3 KLK7 2 
SKP2  3 MMP1 3      DTL  2  LIG1  4  SULT2B1  2 
TK1  3  MMP12  3      EZH2 2 LY75 4 TGM3 2 
TPX2  3 MMP9 3     IL17RB  2 MCM2 5  AREG 2 
UBE2C 3 MYBL2 3      ITPKB  2  MELK  3  CD5  2 
    NUP62 3      KIF15  2 MYBL2 3  ECM1  2 
    PCNA 4      LIG1  2 PCNA 4 EIF5A 2 
   PLAT  3     LOC285084  2 PSMB9 4 EPS8L1 2 
   PLOD2  3     LOC388494  2 RFC4 5  FGFBP1  2 
   PSMB9  3     LOC440331  2 SYCP2 7 GCNT2 2 
    RFC4 4      LY75 2  SYNGR3  4 H2BFS  2 
   SKP2  3      MDM1  2 TK1 3  HIST2H3PS2  2 
   SYCP2  3      MEI1 2 TPX2 4 KIF1C  2 
    TFRC 3     MEIS1 2 TYK2 4 LY6D 2 
    TK1  3     NR1D2 2 TYMS 5 MAOA 2 
    TPX2 3     PIK3R3  2  UBE2C  3 PITX2 2 
    TYK2 3      PSIP1 2 USP1 4  PKP3 2 
    TYMS  3     SLFN13  2     S100P  2 
    UBE2C  3     SMARCA2  2     SERPINB4  2 
       SYCP2  4     SLC24A3  2 
       SYNGR3  3     UGT1A6  2 
       TAF7L  2     WNT4  2 
       TCAM1  2      
       T Y M S   2       
       U S P 1   2       
       WDR76  2      
       ZNF238  2      30    Current Genomics, 2009, Vol. 10, No. 1  Buitrago-Pérez et al. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. (1). Enrichment analysis of Gene Ontology terms within HPV-infected human mucosal carcinoma signatures. Bar plots represent the 
statistical significance of the enrichment (-log10(p-val)) in either overexpressed genes (Signature 5, black bars) or underexpressed genes (Sig-
nature 6, grey bars). 
 
Table 3.  Common Deregulation between HPV-Infected Mucosal Tumors and HPV Models 
Model Study  HPV-Signature  Common  Genes 
Signature 5  CDKN2A, CENPF, MCM2, RFC4 and TK1 
CC progression  Gius 2007 
Signature 6  CDA, CRABP2, KIF1C and KLK11 
Signature 5  None 
Duffy 2003 
Signature 6  KLK7, ECM1, LY6D and SULT2B1 
Signature 5  CDKN2A 
Human Keratino-
cytes 
Wan 2008 
Signature 6  KLK7, KLK10, KLK11, LY6D, SCEL and S100P 
Signature 5  CDC7, CDKN2A, DHFR, EZH2, MCM2, MELK, PCNA, RFC4, TPX2, TYMS and USP1 
Organotypic skin 
Garner-Hamrick 
2004  Signature 6  CDA, EIF5A, KLK8 and KLK13 
Signature 5  CENPF, DTL, EZH2, KIF15, MCM2, MELK and PSMB9 
Hela cell line  Kuner 2007 
Signature 6  HIST2H3PS2 
Signature 5  DHFR, E2F1, LIG1, MCM2, PCNA, RFC4, TYMS and USP1 
pRb/p107/p130 
Signature 6  NA 
Signature 5  CDC7, ECT2, MCM2, TK1, TPX2, TYMS and UBE2C 
Transgenic mice 
pRb/p53 
Signature 6  NA 
NA: non applicable. 
 
suggesting that this analysis model is more similar to HPV-
related carcinomas, possibly because the proliferation/diffe- 
rentiation proccesses of the epidermal cells are better resem-
bled than in cellular non-organotypic cultures. 
  Finally, a number of reports have described that the inhi-
bition of expression of HPV18 E6/E7 genes inserted into the 
HeLa cell genome induced important gene deregulation lead-
ing to growth inhibition and/or cellular senescence [34-38]. Molecular Signature of HPV-Induced Carcinogenesis  Current Genomics, 2009, Vol. 10, No. 1    31 
 
Kuner and collaborators described gene expression changes 
after RNA interference of E6 and E7 oncogenes, showing 
that gene viral interference in HeLa cells repressed genes 
normally induced in cervical tumors, and induced genes that 
appear downregulated in tumors [27]. Comparison with our 
HPV-signatures revealed similar findings. Thus, Signature 5 
genes as CENPF, DTL, EZH2, KIF15, MCM2, MELK and 
PSMB9 are repressed after RNA interference; conversely, 
only HIST2H3PS2, that is normally repressed in HPV-
tumors, was also induced after viral oncogene inhibition 
(Table 3). The comparison corroborates that E6 and E7 on-
cogene viral activity in HeLa cancer cell line is essential to 
maintain molecular determinants of HPV-associated tumori-
genesis. 
MOUSE MODELS OF SKIN CARCINOMAS AND 
SIMILARITIES WITH HPV CARCINOGENESIS 
  Recently, using mouse models we have described the 
phenotypical consequences of the deletion of members of the 
retinoblastoma protein family in the skin homeostasis. Mice 
with conditional deletion of Rb alleles in stratified epithelia 
(K14Cre; Rb
loxP/loxP, thereafter pRb- mice) display increased 
and aberrant cell proliferation, impaired differentiation, and 
the disengagement of these processes as cells committed in 
the differentiation process are still able to proliferate in vivo 
and in vitro [39]. These differences in phenotype are more 
severe with the loss of p107 in K14Cre; Rb
loxP/loxP; Rbl1-/- 
(pRb-; p107-) mice [39]. However, although p107 and p130 
exert overlapping functions in epidermis [40], K14Cre; 
Rb
loxP/loxP; Rbl2-/- (pRb-; p130-) mice were very similar to 
Rb- mice [28]. Importantly, we could correlate the prolifera-
tion differences with specific changes in gene overexpres-
sion between pRb-, pRb-; p107- and pRb-; p130- primary 
keratinocytes using microarray analysis (pRb/p107/p130 
signature), and explain the phenotypes in the context of al-
tered E2F expression and functionality [28]. Comparison of 
the mouse skin pRb/p107/p130 signature mapped to human 
genes with Signature 5 of mucosal HPV-carcinomas re-
vealed a significant overlap of 7 genes: DHFR, E2F1, LIG1, 
MCM2, PCNA, RFC4, TYMS and USP1. 
  On the other hand, although pRb-; p107- mice die soon 
after birth, we have been able to demonstrate that skin trans-
plants from pRb-; p107- onto immunosupressed mice induce 
spontaneous tumors [29]. Again, using microarray analysis 
of pretumoral skin, we have shown that double deletion of 
pRb and p107 produces the reduction of p53-dependent pro-
apoptotic signals, and the increased of E2F-dependent genes 
[29, 41]. Overall, our data demonstrated that p107 behaves 
as a tumor suppressor in epidermis in the absence of pRb. 
We can argue that the overlap observed between pRb/p107/ 
p130 mouse skin signature and the human Signature 5 could 
be partially due to combined loss of pRb, p107, and func-
tional inhibition of p53. We proposed, thus, that pRb-; p107- 
mouse model could be used as a tool to analyze oncogenic 
activities of “high risk” HPVs. 
  On the other hand, we have demonstrated that K14Cre; 
Rb
loxP/loxP; TP53
loxP/loxP mice (pRb-; p53-) and K14Cre; 
TP53
loxP/loxP mice (p53-) develop highly undifferentiated and 
very aggressive spontaneous squamous cell carcinoma in the 
skin [30] that display a high lung metastatic capacity (sub-
mitted). A gene expression microarray comparison between 
normal skin and primary tumors from both genotypes have 
allowed us to extract p53-deficient tumor signatures of over-
expressed and underexpressed genes (unpublished data). 
Human mapped genes revealed an overlap of 7 overex-
pressed genes with those present in HPV-tumors of Signa-
ture 5: CDC7, ECT2, MCM2, TK1, TPX2, TYMS and 
UBE2C. Importantly, these genes were commonly overex-
pressed in pRb-; p53- as well as p53- tumors, highlighting 
that deletion of only the TP53 alleles resulted in tumors dis-
playing similar deregulation than those arising by combined 
Rb and TP53 deletion. Again, these mouse models do exhibit 
similar molecular trends than HPV-human tumors, and could 
possibly be preclinical tools for therapeutic intervention of 
aggressive forms of the disease. 
GENE OVEREXPRESSION IN HPV-TUMORS 
  Many reports have described that HPV-associated tumor 
samples are characterized by the overexpression of cell cycle 
genes. These results are in line with our comparative analy-
sis, in which from a list of 26 genes (Signature 5) commonly 
overexpressed in HPV-carcinomas, half of them are directly 
implicated in different processes of the cell cycle (CDKN2A, 
MYBL2, LIG1, TPX2, CENPF, E2F1, SYCP2, PCNA, 
MCM2, CDC7, CDKN2C, KIF15, and UBE2C), such as 
DNA replication, DNA repair, and cell cycle regulation (Fig. 
(1)). Moreover, there are overexpressed genes involved in all 
phases of cell cycle (G1, G1 to S, and M), which suggests 
that a general deregulation of cellular proliferation is taking 
place in infected tissues. Strikingly, genes that have been 
described to be regulated by active E2F1, as well as E2F1 
itself, are upregulated (MYBL2, MCM2, CDC7, DHFR, 
PCNA, TYMS, EZH2, CDKN2A, and CDKN2C) [42-49]. 
Moreover, there are also genes that contain E2F-responsive 
elements within their promoter sequences but for which no 
transcriptional regulation has yet been described (DTL, 
KIF15, LIG1, MELK, and SYCP2). These findings demon-
strate that pRb-functional interference activity of E7 is ac-
tively taking place in tumors, as the gene deregulation elic-
ited in the HPV-carcinomas is mainly due to E2F activity. 
On the other hand, there are a number of overexpressed 
genes that are also p53-responsive, suggestive of an interfer-
ence with p53 pathway function: MYBL2, EZH2, TYMS, 
DHFR, and ECT2 [50-54]. Interestingly, all but ECT2 are 
genes repressed by p53 and pRb, which suggests that func-
tional inactivation of both tumor suppressors is taking place. 
UNDEREXPRESSED GENES IN HPV-TUMORS 
  Within the Signature 6 genes, it is important to remark 
the presence of various proteases, such as carboxypeptidase 
CPA4, but mostly serine proteases (PRSS3 and kalikreins), 
as well as a serine protease inhibitor SERPINB4. Between 
the serine proteases, 5 members of the kalikrein protein fam-
ily are included: KLK7, KLK8, KLK10, KLK11 and 
KLK13. Some of these kalikrein proteins have been de-
scribed as markers of carcinomas from different organs, al-
though the function for all the members is not yet known. 
However, it has been described that KLK7 is involved in the 
degradation of adhesive proteins of the extracellular part of 
the corneodesmosomes, the junctional structures that medi-
ate corneocyte cohesion, such as corneodesmosin, desmo-32    Current Genomics, 2009, Vol. 10, No. 1  Buitrago-Pérez et al. 
 
glein 1, and desmocollin 1 [55]. As the degradation of these 
proteins at the epidermis surface is necessary for desquama-
tion, the observed deregulation suggests that HPV could 
modulate the degradation of these proteins in order to get a 
proper assembly/release of virus particles during desquama-
tion. On the other hand, two proteins whose expression acti-
vates the p53-pathway are also underexpressed: PITX2 and 
EIF5A [56, 57]. PITX2 encoded protein acts as a transcrip-
tion factor of the RIEG/PITX homeobox family and is in-
volved in Wnt, FGF and TGF-ß signaling [58-61]. Impor-
tantly, Pitx2a isoform can bind to HPV E6 protein and in-
hibit E6/E6AP-mediated p53 degradation. Thus, the repres-
sion of PITX2 contributes to prevent the accumulation of 
functional p53 protein in HPV infected cells [62]. Eukaryotic 
translation initiation factor 5A, is induced by p53 [63], and 
can trigger apoptosis in cancer cells [64]. In conclusion the 
downregulation of both genes is in line with functional inhi-
bition of p53 mediated by E6 oncoprotein. 
CONCLUSIONS 
  The present review is a comparative analysis of pub-
lished list of deregulated genes in relation with high risk 
HPV-infection or E6/E7 oncogene activities, in order to find 
common trends between the different studies. We find gene 
overlaps of over- and under-expressed genes in HPV-
infected human mucosal carcinomas that were validated in a 
model of cervical carcinoma progression [26] and in HeLa 
cells treated with RNA interference against HPV18 E6 and 
E7 oncoproteins [27]. The comparative also shows that cel-
lular systems based on primary human keratinocytes ex-
pressing HPV-oncogenes do not faithfully mimic gene de-
regulation observed in human HPV-carcinomas. The organo-
typic culture is a more similar approach to the in vivo setting, 
probably because it recapitulates proliferation and differen-
tiation processes better than cellular systems. On the other 
hand, comparison with transgenic mouse models of retino-
blastoma family proteins and/or p53 protein ablation from 
stratified epithelia corroborates that these proteins are func-
tionally inhibited in HPV-samples, as they share similar gene 
expression trends. Altogether these observations can help to 
define new targets for the treatment of HPV-mediated car-
cinogenesis. Furthermore, such possible new treatments can 
be tested in preclinical trials in the genetically modified mice 
and in human keratinocyte organotypic cultures as they reca-
pitulate the findings observed in clinical specimens. 
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